Chang Chun-Ming, Jassi Chikondi, Kuo Wei-Wen, Lin Yu-Jung, Chiu Chih-Hao, Wu Tsai-Ting, Kuo Chia-Hua, Ho Tsung-Jung, Lin Shinn-Zong, Huang Chih-Yang
Department of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 970, Taiwan.
School of Medicine, Tzu Chi University Hualien, Taiwan.
Am J Cancer Res. 2025 May 15;15(5):2180-2192. doi: 10.62347/XMGX2636. eCollection 2025.
Breast cancer and its associated drug resistance present significant clinical challenges. From a translational medicine perspective, Traditional Chinese Herbal Medicine (TCHM) offers promising integrative approach to bridge the experimental findings with clinical application, enhancing cancer treatment outcomes and mitigate drug resistance. In this study, we evaluated a TCM herbal formulation, Kang Ru (KR), comprising , each traditionally and experimentally recognized for their potential therapeutic properties. We aimed to evaluate the anti-cancer effects of KR on breast cancer and its potential to enhance the efficacy of the chemotherapeutic agent paclitaxel. Using breast cancer cell lines we evaluated the effects of KR, both alone and in combination with paclitaxel on cell growth, viability, migration, and invasion. We further evaluated the potential of KR in enhancing paclitaxel to reduce tumor progression using a breast cancer xenograft model in mice. Our findings demonstrated that KR significantly inhibited cell growth and migration in breast cancer cell lines. Moreover, the combination of KR with paclitaxel demonstrated synergistic effects, effectively reducing cell viability, inducing cell apoptosis and inhibiting cell migration. In an animal model, the combination of KR and paclitaxel significantly enhanced breast cancer suppression, corroborating the in vitro findings. In conclusion, KR is a novel Chinese herbal formulation, with significant anti-cancer potential, enhancing paclitaxel's efficacy in inhibiting breast cancer progression. These findings suggest that KR could be a promising adjunctive strategy to improve breast cancer treatment and warrant further translational research to facilitate its clinical development as a complementary therapeutic option.
乳腺癌及其相关的耐药性给临床带来了重大挑战。从转化医学的角度来看，传统中药提供了一种很有前景的综合方法，可将实验结果与临床应用联系起来，提高癌症治疗效果并减轻耐药性。在本研究中，我们评估了一种中药复方制剂——抗乳（KR），它由[具体成分未给出]组成，这些成分在传统医学和实验中均因其潜在的治疗特性而得到认可。我们旨在评估KR对乳腺癌的抗癌作用及其增强化疗药物紫杉醇疗效的潜力。我们使用乳腺癌细胞系评估了KR单独以及与紫杉醇联合使用对细胞生长、活力、迁移和侵袭的影响。我们还使用小鼠乳腺癌异种移植模型进一步评估了KR增强紫杉醇减少肿瘤进展的潜力。我们的研究结果表明，KR能显著抑制乳腺癌细胞系中的细胞生长和迁移。此外，KR与紫杉醇联合使用显示出协同作用，有效降低细胞活力、诱导细胞凋亡并抑制细胞迁移。在动物模型中，KR与紫杉醇联合使用显著增强了对乳腺癌的抑制作用，证实了体外实验结果。总之，KR是一种新型中药复方制剂，具有显著的抗癌潜力，能增强紫杉醇抑制乳腺癌进展的疗效。这些发现表明，KR可能是一种有前景的辅助策略，可改善乳腺癌治疗，值得进一步开展转化研究，以促进其作为一种补充治疗选择的临床开发。
